The effect of vinblastine sulfate on the acceptance and growth of a very malignant, human adenocarcinoma of the kidney (RCC1) on nude mice was investigated. Without any treatment, this tumor has an acceptance rate of 100%. Subcutaneously transplanted pieces of tumor, measuring 3 × 3 × 1 mm, commence to grow rapidly 1 week after transplantation and reach a diameter of approximately 2 cm, 6 weeks thereafter. Tumors with a diameter of approximately 2 cm, treated during 6 weeks with vinblastine (0.6 mg/kg/week), continued to grow during treatment and thereafter. However, when these growing, pretreated tumors were transplanted on new experimental animals, they either were not accepted by them or grew very slowly. When animals with tumor transplants were treated for 6 weeks with vinblastine (same schedule as above), beginning on the 1 st day after transplantation, tumor growth was markedly retarded in every case, but only very seldom the tumor was not accepted.

Keywords:
Vinblastine sulfate, Renal cell carcinoma, nu/nu mouse
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.